Stocks · Health care · Pharmaceutical Preparations

Amylyx Pharmaceuticals, Inc.

AMLX Clue Score40

United States Fiscal year ends December CIK 0001658551 Results filed 5 Nov 2026

Add to watchlist

What the insiders did Net selling

Individual transactions

Insider

Date

Role

Action

Price

Amount

Justin B. Klee

16 Jan 2026

Co-Chief Executive Officer

Sold after exercise

1,995

$13.89

$27.70K

Joshua B Cohen

16 Jan 2026

Co-Chief Executive Officer

Sold after exercise

1,974

$13.83

$27.30K

Justin B. Klee

15 Jan 2026

Co-Chief Executive Officer

Sold after exercise

136,193

$13.58

$1.85M

Joshua B Cohen

15 Jan 2026

Co-Chief Executive Officer

Sold after exercise

136,193

$13.59

$1.85M

Show all 35 transactions →

What was left out

Form 4 filings counted 42

Amendments (4/A) skipped 0

Filings about a different issuer 0

Unreadable filings 0

Joint filings 0

Sales on a Rule 10b5-1 plan 3

Sales straight out of an exercise 4

Sales at will 24

Transactions with no price 0

Shares from compensation/vesting 1,419,126

History held since 10 Jan 2022